Results 41 to 50 of about 83,877 (250)

Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis [PDF]

, 2018
Background Few risk factors have been identified for the development of calcinosis among patients with Juvenile Dermatomyositis, and currently no clinical phenotype has been associated with its development.
Al-Hammadi, Noor, Baszis, Kevin W, CARRA Legacy Registry Investigators,, Dharnidharka, Vikas R, Orandi, Amir B   +4 more
core   +2 more sources

Older Adults and Immune Thrombocytopenia: Considerations for the Clinician

Clinical Interventions in Aging, 2023
Etienne Crickx,1,2 Matthieu Mahévas,1,3,4 Marc Michel,1 Bertrand Godeau1 1Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy ...
Crickx E, Mahévas M, Michel M, Godeau B
doaj  

Guillain-Barré syndrome: a century of progress [PDF]

, 2016
In 1916, Guillain, Barré and Strohl reported on two cases of acute flaccid paralysis with high cerebrospinal fluid protein levels and normal cell counts — novel findings that identified the disease we now know as Guillain–Barré syndrome (GBS).
A Campbell, A Chiba, A Chiba, A Pestronk, A Uncini, AA Ilyas, AD Langmuir, AJ Sumner, AK Asbury, AK Asbury, AK Asbury, AM Fitzpatrick, B Parra, B van den Berg, BH Waksman, C Brechenmacher, C Fokke, C Hafer-Macko, C Linington, CE Hafer-Macko, CL Schengrund, CP O'Leary, E Díez-Tejedor, FG van der Meché, FH Geisler, G Guillain, GM McKhann, GM O'Hanlon, H Wis´niewski, HJ Willison, Hugh J. Willison, J Kaldor, J Matias-Guiu, JA Goodfellow, JC Dodge, JG McLeod, JH Rees, JJ Plomp, JM Pearce, John A. Goodfellow, JW Albers, JW Griffin, JW Prineas, K Kaida, K Susuki, KE Astrom, KM Rhodes, KN Greenshields, LB Schonberger, LD Osler, LM Araujo, LT Kurland, M Fisher, M Kadlubowski, M Vermeulen, MK White, N Shahrizaila, N Yuki, N Yuki, N Yuki, N Yuki, NA Gregson, O Landry, PA van Doorn, PO Osterman, R McGonigal, R McGonigal, R van Koningsveld, RA Hughes, RA Hughes, RJ Greenwood, RP Kleyweg, S Draganescu, S Kusunoki, S Lafontaine, S Rinaldi, S Rinaldi, S Rinaldi, SK Halstead, SK Halstead, SK Halstead, T Lasky, T Saida, TE Feasby, TE Feasby, TW Ho, TW Ho, VM Cao-Lormeau, W Wiederholt, W Yan, WE Haymaker, Y Nagai   +91 more
core   +1 more source

IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety

Therapeutic Advances in Neurological Disorders, 2018
Objectives: Small-fiber polyneuropathy (SFPN) has various underlying causes, including associations with systemic autoimmune conditions. We have proposed a new cause; small-fiber-targeting autoimmune diseases akin to Guillain-Barré and chronic ...
Xiaolei Liu, R. Treister, M. Lang, A. Oaklander   +3 more
semanticscholar   +1 more source

A Case of Statin-Associated Autoimmune Myopathy. [PDF]

, 2017
A 70-year-old previously independent man developed progressive proximal leg weakness resulting in a fall at home suffering traumatic brain injury. He was prescribed a statin medication two years prior, but this was discontinued on admission to the ...
Dokukin, Andrei N, Farjami, Sassan, Kaiser, Cassandra J, Leung, Anthony, Romansky, Stephen, Strube, Sarah J, Sweidan, Alexander J   +6 more
core   +3 more sources

A Comparison Between 1 Day versus 7 Days of Sepsis in Mice with the Experiments on LPS-Activated Macrophages Support the Use of Intravenous Immunoglobulin for Sepsis Attenuation

Journal of Inflammation Research, 2021
Jiradej Makjaroen,1 Arthid Thim-Uam,2 Cong Phi Dang,3 Trairak Pisitkun,1 Poorichaya Somparn,1,4 Asada Leelahavanichkul4– 6 1Center of Excellence in Systems Biology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 2Division of ...
Makjaroen J, Thim-Uam A, Dang CP, Pisitkun T, Somparn P, Leelahavanichkul A   +5 more
doaj  

Clinical and laboratory parameter analysis in patients with common Variable Immunodeficiency [PDF]

Medicinski Podmladak, 2022
Introduction: Common Variable Immunodeficiency (CVID) is the most prevalent primary immunodeficiency in adult population. The diagnosis is based on low concentration of at least 2 immunoglobulin classes, mostly IgG, with low IgA and/or IgM.
Krtinić Danka, Stojanović Maja
doaj  

Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG

Journal of Clinical Immunology, 2019
Patients with primary immunodeficiency disease (PIDD) and antibody deficiency require lifelong immunoglobulin replacement therapy. While both subcutaneous immunoglobulin (SCIG) and intravenous immunoglobulin (IVIG) replacement therapy are effective in ...
C. Anterasian, R. Duong, P. Gruenemeier, C. Ernst, Jessica Kitsen, B. Geng   +5 more
semanticscholar   +1 more source

Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. [PDF]

, 2016
OBJECTIVE: To study rituximab in pediatric neuromyelitis optica (NMO)/NMO spectrum disorders (NMOSD) and the relationship between rituximab, B cell repopulation, and relapses in order to improve rituximab monitoring and redosing.
Alper, G, Appleton, R, Banwell, B, Benson, La, Brilot, F, Dale, R. C., Deiva, K, Gorman, Mp, Leventer, Rj, Mohammad, Ss, Nolan, M, Nosadini, M, Ramanathan, S, Riney, Cj, Waldman, At   +14 more
core   +1 more source

Thromboembolic risk with IVIg

Neurology, 2019
Our objective was to evaluate whether IV immunoglobulin (IVIg) increases the risk of thromboembolic events in neurology outpatients with inflammatory neuropathies, as there is conflicting evidence supporting this hypothesis, mainly from non-neurologic ...
M. Kapoor, J. Spillane, Christina Englezou, Scherezade Sarri-Gonzalez, R. Bell, A. Rossor, H. Manji, M. Reilly, M. Lunn, A. Carr   +9 more
semanticscholar   +1 more source